GlassScriptPhysician profile
Virginia J Smith
NPI 1568827095
$11,323.26
in general payments reported to CMS, 2019-2025
32 companies · $3,418 in 2025
The $3,418 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,875 · 2022: $2,114 · 2023: $2,359 · 2024: $1,557 · 2025: $3,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,334.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,051.48 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $1,575.16 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,172.14 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,151.81 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $662.32 | 2022-2025 | Austedo, Austedo Xr, Austedo Xr |
| Harmony Biosciences LLC | $614.66 | 2022-2025 | Wakix |
| Neurocrine Biosciences, INC. | $554.86 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $469.54 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $428.07 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $387.29 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $325.76 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $237.75 | 2022-2025 | Auvelity, Sunosi |
| Idorsia Pharmaceuticals US INC | $215.67 | 2023-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $215.01 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $161.04 | 2021-2025 | Trintellix |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $159.60 | 2021-2022 | |
| Almatica Pharma LLC | $147.42 | 2021-2025 | Loreev Xr |
| Bausch Health US, LLC | $126.73 | 2021-2023 | Wellbutrin, Aplenzin |
| Corium, LLC | $107.05 | 2022-2023 | Azstarys |
| Neos Therapeutics, LP | $106.68 | 2021-2024 | Adzenys Xr-Odt |
| Eisai INC. | $73.70 | 2021-2024 | |
| Noven Therapeutics, LLC | $68.06 | 2025 | Xelstrym, Secuado |
| Indivior INC. | $59.68 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $47.27 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $39.82 | 2022 | |
| Ironshore Pharmaceuticals INC. | $33.45 | 2024 | |
| Azurity Pharmaceuticals, INC. | $26.93 | 2023-2024 | Horizant, Horizant |
| Avadel Cns Pharmaceuticals, LLC | $26.84 | 2025 | Lumryz |
| Merck Sharp & Dohme LLC | $24.92 | 2022 | |
| Adlon Therapeutics L.P. | $24.64 | 2021 | |
| Tris Pharma INC | $16.00 | 2023 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.